NASDAQ · Biotechnology

Merrimack Pharmaceuticals, Inc. (MACK) Stock

$15.15 +0.10% NASDAQ: MACK Healthcare

Founded in 1993, Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts.

Valuation

MetricValue
Price$15.15
Market Cap$223.97M
P/E Ratio-183.35
P/B Ratio11.55
P/S Ratio0.00
EPS (TTM)$-0.08
52-Week High$15.89
52-Week Low$11.53
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-6.22%
ROA-6.15%
ROCE-11.61%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio43.50

Annual Financials (USD)

Metric20192020202120222023
Revenue$0$0$0$0$0
Operating Profit$-22.0M$-3.0M$-2.0M$-2.0M$-2.0M
Net Profit$-21.0M$-3.0M$-2.0M$-2.0M$-1.0M
EPS$-1.59$-0.23$-0.18$-0.11$-0.08
Op Margin—————

Balance Sheet (USD)

Metric20192020202120222023
Total Assets$20.0M$17.0M$15.0M$20.0M$19.0M
Total Liabilities$3.0M$1.0M$1.0M$1.0M$0
Cash$17.0M$14.0M$14.0M$19.0M$6.0M
Borrowings$0$0$0$0$0

Latest News

NYLI MacKay DefinedTerm Muni Opportunities Fund Declares Monthly Dividend Distributions for the Months of July, August, and September 2026 Business Wire · Jul 1, 2026

Cash Flow (USD)

Metric20192020202120222023
Operating Cash Flow$-31.0M$-5.0M$0$-2.0M$-2.0M
Investing Cash Flow$70.0M$2.0M$0$0$-12.0M
Financing Cash Flow$-16.0M$0$0$7.0M$1.0M
Net Cash Flow$-4.0M$-3.0M$0$5.0M$-13.0M
Free Cash Flow$-31.0M$-5.0M$0$-2.0M$-2.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.06
EV / EBITDA216.47
FCF Yield-0.68%
Quick Ratio43.50
Interest Coverage—
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
CATBCatabasis Pharmaceuticals, Inc. $8.54 -6.97% -5.08 $234.86M 0.00%
CBLICytocom, Inc. $3.17 -7.31% -16.68 $226.39M 0.00%
CRGXCARGO Therapeutics, Inc. Common Stock $4.47 +0.00% -1.59 $216.19M 0.00%
INXBInhibrx Biosciences, Inc. $15.86 +13.94% -12.41 $225.87M 0.00%
SLRNAcelyrin, Inc. $2.27 +0.00% -0.91 $229.17M 0.00%

About Merrimack Pharmaceuticals, Inc.

Founded in 1993, Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts.

Merrimack Pharmaceuticals, Inc. is headquartered in US.

Merrimack Pharmaceuticals, Inc. (MACK) stock trades at $15.15 with a market capitalization of $223.97M. The stock is valued at a negative price-to-earnings (P/E) ratio of -183.35, reflecting a net loss over the last twelve months, price-to-book of 11.55, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $11.53 and $15.89, and currently trades 4.7% below its 52-week high.

On profitability, Merrimack Pharmaceuticals, Inc. generates a return on equity (ROE) of -6.22% (negative, reflecting a net loss), return on capital employed of -11.61%.

Official website: www.merrimack.com

Related Healthcare Stocks

LLY Eli Lilly and Company $1211.40 +3.85% JNJ Johnson & Johnson $253.91 +2.13% ABBV AbbVie Inc. $283.52 +3.34% MRK Merck & Company, Inc. Common Stock (new) $147.37 +3.79% UNH UnitedHealth Group Incorporated Common Stock (DE) $395.62 +4.73% NVS Novartis AG $146.88 +3.14% AZN AstraZeneca PLC $162.03 +3.99% TMO Thermo Fisher Scientific Inc $673.20 +1.53% AMGN Amgen Inc. $426.11 +3.21% GILD Gilead Sciences, Inc. $153.54 +3.80% ABT Abbott Laboratories $102.97 +0.35% NVO Novo Nordisk A/S $38.12 +0.16%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.